B
Bull
Bull · 25%REVB
$3.08
Precio del escenario
$1.050
+0.020 (+1.94%)Al cierre
Loading chart…
- High
- 1.080
- Open
- 1.040
- VWAP
- 1.04
- Vol
- 20.31K
- Mkt Cap
- 3.04M
- Low
- 1.000
- Amount
- 21.19K
- EV/EBITDA, TTM
- 0.00
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The Company's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The Company has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.
AI analysis of Revelation Biosciences Inc (REVB)
holdRevelation Biosciences Inc is not a strong buy at the moment due to ongoing financial losses and volatility, despite a promising analyst target of $16. The current price is $1.05, with a year-to-date change of -67.72%. The main risk is the significant net loss of $59.76 million reported for FY 2025, which raises concerns about future profitability and funding needs.
Analyst Ratings (1)
Buy
1 Buy
0 Hold
0 Sell
Current: 1.05
Mínimo
—
Promedio
—
Máximo
—
Roth Capital
Buy
$16
2026-03-30
Roth Capital
2026-03-30
Precio objetivo
$16
Buy
Roth Capital
Buy
$16
2026-02-27
Roth Capital
2026-02-27
Precio objetivo
$16
Buy
Roth MKM
Strong Buy
$450
2023-02-14
Roth MKM
2023-02-14
Precio objetivo
$450
Strong Buy
Roth Capital
Strong Buy
$12600
2022-02-17
Roth Capital
2022-02-17
Precio objetivo
$12600
Strong Buy
Métricas de valoración
The current forward P/E ratio for Revelation Biosciences Inc (REVB) is 0.89, compared to its 5-year average forward P/E of -2.83.
Alphio AI Price Scenarios for REVB
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
9.008-19NewsfilterRevelation Biosciences Selects Avance Clinical for Phase 2/3 TITAN Study
9.505-08seekingalphaRevelation Biosciences Reports Q1 2026 Financial Results
- 9.502-27seekingalpha
Revelation Biosciences Reports FY Net Loss
2.001-26stocktwitsRevelation Biosciences Executes Third Reverse Stock Split in a Year
9.001-23NASDAQ.COMRevelation Biosciences (REVB) Secures FDA Agreement for Gemini Drug's Clinical Trial Pathway
REVB FAQ — answered by Alphio AI
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The Company's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The Company has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Revelation Biosciences Inc is not a strong buy at the moment due to ongoing financial losses and volatility, despite a promising analyst target of $16. The current price is $1.05, with a year-to-date change of -67.72%. The main risk is the significant net loss of $59.76 million reported for FY 2025, which raises concerns about future profitability and funding needs.
1 analysts cover REVB: 1 rate it Buy, 0 Hold and 0 Sell.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.